重大事项：
科笛-B(02487)：CU-10201(外用4%米诺环素泡沫剂)已获得国家药监局上市批准
和誉-B(02256)：匹米替尼治疗TGCT患者的MANEUVER关键3期研究取得积极顶线结果及匹米替尼治疗TGCT的最新1期研究结果
中国燃气(00384)：壹品慧已向美国证交会递交可能进行发售的注册声明草拟本
歌礼制药-B(01672)完成ASC40(地尼法司他)每日一次口服片治疗痤疮III期临床试验患者入组
宜明昂科-B(01541)：IMM01(替达派西普)联合阿扎胞苷进行CMML一线治疗的III期临床试验完成首例患者给药
石药集团(01093)：二价人乳头瘤病毒mRNA治疗性疫苗(SYS6026)获临床试验批准
东阳光长江药业(01558)：东阳光药与 Apollo 公司就开发及商业化HEC88473 项目达成授权许可协议
四环医药(00460)拟分拆轩竹生物的股份并于联交所主板上市
经营业绩：
百济神州(06160)第三季度总收入10.02亿美元 同比增加28%
上海实业环境(00807)公布前9个月业绩 股东应占净利润达4.996亿元 毛利率增至37.7%
华润置地(01109)10月总合同销售金额约310.0亿元 同比增长12.4%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.